Loading clinical trials...
Loading clinical trials...
A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS
Conditions
Interventions
20-valent pneumococcal conjugate vaccine
13-valent pneumococcal conjugate vaccine
Locations
110
United States
Children's of Alabama
Birmingham, Alabama, United States
UAB Pediatric Primary Care Clinic at Children's of Alabama
Birmingham, Alabama, United States
Southeastern Pediatric Associates
Dothan, Alabama, United States
MedPharmics, LLC
Phoenix, Arizona, United States
Northwest Arkansas Pediatrics
Fayetteville, Arkansas, United States
The Children's Clinic of Jonesboro, P.A.
Jonesboro, Arkansas, United States
Start Date
May 20, 2020
Primary Completion Date
September 2, 2022
Completion Date
September 2, 2022
Last Updated
December 6, 2023
NCT07205289
NCT06731374
NCT06044077
NCT06790290
NCT05569954
NCT07019909
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions